Cardiovascular Drug Delivery
Technologies, Companies & Markets

By
Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

October 2018

A Jain PharmaBiotech Report
AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.


ABOUT THIS REPORT

The original report on Cardiovascular Drug Delivery appeared as a chapter in the author's Drug Delivery Systems published by Decision Resources Inc in 1998. The second edition was published by Informa Pharmaceuticals after detaching Cancer Drug Delivery and Central Nervous System Drug Delivery. Cardiovascular Drug Delivery has now been detached, expanded and updated to be issued as separate publications by Jain PharmaBiotech.
# TABLE OF CONTENTS

0. Executive Summary .............................................................................................................. 10

1. Cardiovascular Diseases ....................................................................................................... 12
   Introduction .......................................................................................................................... 12
   History of cardiovascular drug delivery .............................................................................. 12
   Overview of cardiovascular disease .................................................................................. 13
      Coronary artery disease .................................................................................................. 13
      Angina pectoris ............................................................................................................... 13
      Myocardial infarction ...................................................................................................... 13
      Limitations of current therapies for myocardial ischemic disease ............................... 14
      Cardiomyopathies ........................................................................................................... 14
      Cardiac arrhythmias ...................................................................................................... 14
      Congestive heart failure ............................................................................................... 15
      Peripheral arterial disease ............................................................................................ 15
      Current management ...................................................................................................... 16
      Atherosclerosis .............................................................................................................. 16
      The endothelium as a target for cardiovascular therapeutics ....................................... 16
   Molecular cardiology ........................................................................................................... 16
      Cardiogenomics .............................................................................................................. 16
      Cardioproteomics .......................................................................................................... 17
   Personalized cardiology ....................................................................................................... 18
      Pharmacogenomics of cardiovascular disorders ......................................................... 18
      Modifying the genetic risk for myocardial infarction .................................................... 18
      Management of heart failure ......................................................................................... 19
      Management of hypertension .......................................................................................... 19
      Pharmacogenomics of diuretic drugs ........................................................................... 20
      Pharmacogenomics of ACE inhibitors ......................................................................... 20
      Management of hypertension by personalized approach ............................................. 20
      Pharmacogenetics of lipid-lowering therapies .............................................................. 20
      Polymorphisms in genes involved in cholesterol metabolism ..................................... 21
      Role of eNOS gene polymorphisms ............................................................................ 21
   Important advances in cardiovascular therapeutics ......................................................... 22
   Drug delivery, biotechnology and the cardiovascular system ........................................... 22
   Role of cardiovascular imaging in cardiovascular therapeutics ....................................... 23
   Biologic therapeutics for cardiovascular disorders ......................................................... 23
   Chronopharmacotherapy of cardiovascular diseases ...................................................... 23

2. Methods for Drug Delivery to the Cardiovascular System .............................................. 26
   Introduction ......................................................................................................................... 26
   Routes of drug delivery to the cardiovascular system ....................................................... 26
   Local administration of drugs to the cardiovascular system ............................................ 26
      Intramyocardial drug delivery ....................................................................................... 26
      Drug delivery via coronary venous system .................................................................... 27
      Intrapericardial drug delivery ....................................................................................... 27
   Formulations for drug delivery to the cardiovascular system .......................................... 28
      Sustained and controlled release .................................................................................. 28
      Programming the release at a defined time ................................................................... 29
      Dosage formulation of calcium channel blockers ....................................................... 29
      Sustained and controlled release verapamil ................................................................. 29
      Methods of administration of proteins and peptides .................................................... 29
      Delivery of peptides by subcutaneous injection ......................................................... 30
      Depot formulations and implants .............................................................................. 30
      Poly(ethylene glycol) technology .............................................................................. 30
      Liposomes for cardiovascular drug delivery .............................................................. 31
      Microencapsulation for protein delivery ..................................................................... 31
      Oral delivery of proteins and peptides ........................................................................ 31
   Monoclonal antibodies for cardiovascular disorders ....................................................... 33
      Abciximab ..................................................................................................................... 34
      Canakinumab .............................................................................................................. 34
      PCSK9 MAbs .............................................................................................................. 34
   DDS to improve systemic delivery of cardiovascular drugs .............................................. 34
   Nanotechnology-based drug delivery ............................................................................... 35
      Controlled delivery of nanoparticles to injured vasculature ...................................... 36
      Nanoparticles for cardiovascular imaging and targeted drug delivery ..................... 36
      Nanofiber-based scaffolds with drug-release properties ............................................. 37
   Targeted drug delivery to the cardiovascular system ..................................................... 37
3. Cell Therapy for Cardiovascular Disorders ........................................... 68

3.1. Inducing the proliferation of cardiomyocytes ........................................ 68
3.2. Role of stem cells in repair of the heart ............................................. 68
3.3. Cell-mediated immune modulation for chronic heart disease .............. 68
3.4. Cell therapy for atherosclerotic coronary artery disease ................... 69
3.5. Transplantation of myoblasts for myocardial infarction ..................... 69
3.6. MyoCell™ (Bioheart) ........................................................................ 70
3.7. Transplantation of cardiac progenitor cells for regeneration of cardiac tissue . 71

3.2. Methods of delivery of cells to the heart ........................................... 71

- 4 -
Gene Techniques of gene therapy for cardiovascular diseases

Coronary artery disease with angina pectoris

Hypertension

Apolipoprotein E deficiency

Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles

Gene delivery to vascular endothelium

Ultrasound microbubbles for cardiovascular gene delivery

Direct plasmid injection into the myocardium

Regeneration of cardiomyocytes without use of cardiac stem cells

Prospects of adult stem cell therapy for repair of heart failure

Repair of the damaged heart

4. Gene Therapy for Cardiovascular Disorders

Introduction

Techniques of gene transfer to the cardiovascular system

Direct plasmid injection into the myocardium

Catheter-based systems for vector delivery

Ultrasound microbubbles for cardiovascular gene delivery

Vectors for cardiovascular gene therapy

AAV vectors for therapeutic delivery to the heart

Adenoviral vectors for cardiovascular diseases

Plasmid DNA-based delivery in cardiovascular disorders

Hypoxia-regulated gene therapy for myocardial ischemia

Angiogenesis and gene therapy of ischemic disorders

Therapeutic angiogenesis vs. vascular growth factor therapy

Gene painting for delivery of targeted gene therapy to the heart

Gene delivery to vascular endothelium

Overexpression of eNOS to improve vasodilation with Ad vectors

Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles

Gene therapy for genetic cardiovascular disorders

Gene therapy for acquired cardiovascular diseases

Coronary artery disease with angina pectoris

Ad5FGF-4

Ischemic heart disease with myocardial infarction

angiogenesis for cardiovascular disease

Myocardial repair with IGF-1 therapy

miRNA gene therapy for ischemic heart disease

Congestive heart failure

Rationale of gene therapy in CHF

AAV-mediated gene transfer for CHF

AngioCell gene therapy for CHF

B-ARKct gene therapy

Elevating cardiac dATP by gene therapy to improve cardiac function
5. Drug-Eluting Stents .................................................. 116

Introduction .................................................. 116
Percutaneous transluminal coronary angioplasty .......... 116
Stents .................................................. 116

Restenosis .................................................. 116
Pathomechanism .......................................... 117
Treatment ................................................. 117
Nitric oxide-based therapies for restenosis ............ 118
Carbon monoxide inhalation for preventing restenosis .. 118
Antisense approaches for prevention of restenosis after angioplasty .......... 119
Gene therapy to prevent restenosis after angioplasty .. 119
Delivery of gene therapy for restenosis ............... 119
HSV-1 gene therapy to prevent intimal hyperplasia ..... 119
miRNA-based gene therapy for restenosis following angioplasty ...... 120
Nonviral gene therapy to prevent intimal hyperplasia .. 120
NOS gene therapy for restenosis ....................... 120
Targets for gene therapy for restenosis ............... 121
Viral vector-mediated gene therapy for restenosis ...... 122

Drug delivery devices for restenosis ................. 123
Local drug delivery by catheter ....................... 123
Stenosis associated with stents ....................... 124
Absorbable metal stents ................................ 124

Drug-eluting stents .................................. 124
Various types of DES ................................ 125
CYPHER® sirolimus-eluting coronary stent ............. 125
Dexamethasone-eluting stents ......................... 125
NO-generating stents ................................ 126
Paclitaxel-eluting stents ................................ 126
Sirolimus-eluting vs paclitaxel-eluting stents .......... 127
Novel technologies for DES .......................... 127
Bio-absorbable DES .................................. 127
Drug-eluting stents coated with polymer surfaces .... 128
Endeavour DES ..................................... 128
Polymer-free drug-coated stent for patients at high risk of bleeding .. 129
Stents for delivery of gene therapy .................... 130
Stem cell-based stents .............................. 130
VAN 10-4 DES .................................. 131
Nanotechnology-based stents ..................... 131
6. Markets for Cardiovascular Drug Delivery .................................................. 158

Introduction .................................................................................. 158
Epidemiology of cardiovascular disease ............................................. 158
Cost of care of cardiovascular disorders ............................................. 159
Cardiovascular markets according to important diseases ................. 160
  Antithrombotics ........................................................................... 160
  Anticholesterol agents .................................................................. 160
  Antihypertensive agents ................................................................. 161
  Drugs for congestive heart failure .................................................. 161
Markets for innovative technologies for cardiovascular disorders ........ 161
  Markets for cell therapy of cardiovascular disorders ....................... 161
  Markets for gene therapy of cardiovascular disorders ..................... 162
Markets for drug-eluting stents ......................................................... 162
  Major players in DES market ......................................................... 162
  Impact of safety issues on future markets for DES .......................... 162
  DES market in Asia ..................................................................... 162
  Patenting and legal issues of DES .................................................. 164
  The financial impact of DES on cardiovascular markets ................. 164
Unmet needs for cardiovascular drug delivery .................................... 165
Role of DDS in developing cardiovascular markets ...................................................... 165
Markets for cardiovascular devices ................................................................................. 166
Marketing of innovative cardiovascular drug delivery devices ..................................... 166
Direct to consumer advertising of DES ............................................................................. 166
Future trends in the integration of drug delivery with therapeutics ................................. 167
Future of cardiovascular drug delivery ............................................................................. 167

7. Companies involved in Cardiovascular Drug Delivery ................................. 168
Profiles of companies ........................................................................................................ 168
Collaborations ..................................................................................................................... 255

8. References ....................................................................................................................... 258

Tables
Table 1-1: Landmarks in the historical evolution of cardiovascular drug delivery ................. 12
Table 1-2: Approaches to management of myocardial infarction and its sequela .................. 13
Table 1-3: Gene polymorphisms that alter cardiovascular response to drugs ...................... 18
Table 2-1: Routes of drug delivery used for treatment of cardiovascular disorder ................ 26
Table 2-2: Formulations for drug delivery to the cardiovascular system ............................. 28
Table 2-3: Monoclonal antibodies used for cardiovascular disorders ................................. 33
Table 2-4: Improved methods of systemic drug delivery of cardiovascular drugs ................. 35
Table 2-5: Targeted delivery of therapeutic substances to the cardiovascular system .......... 38
Table 2-6: Classification of devices for drug delivery to the cardiovascular system ............. 39
Table 2-7: Various methods of delivery of therapeutic agents for hypertension ................. 43
Table 2-8: Marketed controlled/ extended release preparation for hypertension ................. 45
Table 2-9: Methods of delivery of nitrate therapy in angina pectoris ................................... 47
Table 2-10: Drug delivery in ischemic heart disease ......................................................... 49
Table 2-11: Strategies for cardioprotection ........................................................................... 52
Table 2-12: Drug delivery for peripheral arterial disorders ............................................... 60
Table 3-1: Clinical trials of cell therapy in cardiovascular disease ..................................... 80
Table 4-1: Cardiovascular disorders for which gene therapy is being considered ............... 88
Table 4-2: Catheter-based systems for vector delivery to the cardiovascular system .......... 89
Table 4-3: Potential applications of antisense in cardiovascular disorders .......................... 109
Table 4-4: Companies involved in gene therapy of cardiovascular diseases ...................... 115
Table 5-1: Treatment of restenosis ...................................................................................... 117
Table 5-2: Devices used for drug delivery in restenosis ...................................................... 123
Table 5-3: Companies involved in drug-eluting stents ....................................................... 135
Table 6-1: Prevalence of cardiovascular disorders in major markets: US 2017-2027 ............ 159
Table 6-2: Prevalence of cardiovascular disorders in major markets: Europe 2017-2027 ....... 159
Table 6-3: Prevalence of cardiovascular disorders in major markets: Japan 2017-2027 ......... 159
Table 6-4: Values of cardiovascular DDS in major markets 2017-2027 ............................. 160
Table 6-5: Markets for innovative technologies for cardiovascular disorders 2017-2027 ....... 161
Table 7-1: Top 5 companies in cardiovascular drug delivery ............................................. 168
Table 7-2: Collaborations in cardiovascular drug delivery ................................................ 255

Figures
Figure 1-1: Drug delivery, biotechnology and cardiovascular diseases ................................. 22
Figure 2-1: MicroSyringe for periarterial injection .............................................................. 41
Figure 2-2: Patch for delivery of follistatin-like 1 factor for myocardial infarction .............. 52
Figure 2-3: Lipoprotein metabolism in ANGPTL3 deficiency .............................................. 66
Figure 5-1: Vicious circle of vascular occlusion following angioplasty and stenting ........... 118
Figure 5-2: Measurement of in-stent stenosis ..................................................................... 124
Figure 5-3: Medtronic’s Endeavour drug-eluting stent ....................................................... 129
Figure 5-4: Magnetic nanoparticle-coated stent ................................................................. 133
Figure 6-1: Unmet needs for cardiovascular drug delivery ................................................ 165